NEUBASE THERAPEUTICS INC (NBSE) Stock Income Statement
NASDAQ:NBSE - Nasdaq - US64132K2015 - Common Stock - Currency: USD
| TTM (2023-9-30) | 2022 (2022-9-30) | 2021 (2021-9-30) | 2020 (2020-9-30) | 2019 (2019-9-30) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 13.38M | 33.32M | 26.57M | 17.07M | 25.51M | |||
| Research and Development | 4.26M | 21.45M | 14.36M | 6.95M | 16.41M | |||
| Selling, General, and Administrative Expenses | 9.12M | 11.87M | 12.20M | 10.12M | 9.10M | |||
| Operating Income | -13.38M | -33.32M | -26.57M | -17.07M | -25.51M | |||
| Interest Income/Expense | 610.00K | -290.00K | -240.00K | -270.00K | -130.00K | |||
| Other Income/Expense | 950.00K | -170.00K | 1.40M | -40.00K | -490.00K | |||
| Non Recurring Items | -1.88M | -650.00K | N/A | N/A | N/A | |||
| Income Before Taxes | -13.73M | -33.78M | -25.41M | -17.38M | -26.13M | |||
| Income Tax | N/A | N/A | N/A | 0.00 | 0.00 | |||
| Net Income | -13.73M | -33.78M | -25.41M | -17.38M | -26.13M | |||
| EBITDA | -13.44M | -32.55M | -26.17M | -16.79M | -25.38M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -7.79 | -20.85 | -18.54 | -17.72 | -63.73 | |||
| Non GAAP EPS | -11.44 | -16.24 | -0.92 | -0.89 | N/A | |||
| Statistics | ||||||||
All data in USD